18 and older, any sex, with Cystic Fibrosis or Motor Neuron Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Patient / Caregiver Satisfaction ScoresPrimary· 90 days
The primary efficacy variable was patient and/or caregiver satisfaction with therapy, as evaluated using a Therapy Use Rating Questionnaire.
The questionnaire was used to assess change in satisfaction or effectiveness on a variety of parameters.
The satisfaction score was completed by the patient, if possible. Some of the patients in this study had Motor Neuron Disease. This disease can compromise the ability of the patient to interact and to respond to questions. In situations where patients could not respond, caregivers were asked to respond on their behalf.
Difficulty of Use (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
4
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
4
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Missed Treatment (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Bring up sputum (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
4
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
3
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Shortness of breath (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Lungs stay healthy (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
3
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
4
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Ability to perform tasks (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Difficulty of Use (Day 90)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
3
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
3
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Missed Treatment (Day 90)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
3
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
3
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Patient / Caregiver Satisfaction ScoresPrimary· 90 days
The Therapy Use Rating Questionnaire is an assessment of patient/caregiver satisfaction with the therapy and their subjective assessment of the benefit of the therapy.
The questionnaire was used to assess change in satisfaction or effectiveness on a variety of parameters.
The satisfaction score was completed by the patient, if possible. Some of the patients in this study had Motor Neuron Disease This disease can compromise the ability of the patient to interact and to respond to questions. In situations where patients could not respond, caregivers were asked to respond on their behalf.
Effective (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Easy to perform (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
2
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Like to continue MN4000 (Day 30)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Effective (Day 90)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
3
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Easy to perform (Day 90)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Like to continue MN4000 (Day 90)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
0
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
0
Mean Percentage Adherence to Prescribed Treatment RegimenSecondary· 90 days
Adherence to the treatment regimen was calculated for each patient (number of minutes of therapy performed / number of minutes of therapy prescribed). The adherence percentage calculated for each study subject was then used to calculate the of Mean adherence to prescribed treatment regimen for the group or groups.
Group
Value
95% CI
Patients With CF Who Required Home Based Airway Clearance With Metaneb
97
86 – 100
Patients With MND Who Required Home Based Airway Clearance With Metaneb
95
89.7 – 99.5
ALS-Functional Rating Scale (ALS-FRS)Secondary· 90 days
MND patients only. The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) is an instrument for evaluating the functional status of patients with Amyotrophic Lateral Sclerosis. It can be used to monitor functional change in a patient over time.
It contains 10 distinct measures:
* Speech
* Salivation
* Swallowing
* Handwriting
* Cutting food and handling utensils (with or without gastrostomy)
* Dressing and hygiene
* Turning in bed and adjusting bed clothes
* Walking
* Breathing
* Climbing stairs
These 10 parameters are scored on a scale of 0-4, based on the patients' ability to p
Bulbar Sub-Score at Baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
10.8
± 1.64
Bulbar Sub-Score after 30 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
10.0
± 3.39
Bulbar Sub-Score after 90 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
10.4
± 3.05
Respiratory Sub-score at baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
9.4
± 1.52
Respiratory Sub-score after 30 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
10.2
± 1.10
Respiratory Sub-score after 90 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
10.2
± 1.10
Total Score at Baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
33.6
± 6.84
Total Score after 30 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
32.0
± 5.29
Cystic Fibrosis Questionnaire - Revised (CFQ-R)Secondary· 90 days
CF patients only. The Cystic Fibrosis Questionnaire (CFQ) is a disease-specific instrument that measures health-related quality of life (HRQoL) for adolescents and adults with cystic fibrosis (CF) \> or = 14 years, consisting of 44 items on 12 generic and disease-specific scales. It offers 5 distinct 4-point Likert scales (e.g., always/often/ sometime/never). Scores for each HRQoL domain; after recoding, each item is summed to generate a domain score and standardized. Scores range from 0 to 100, with higher scores indicating better health.
Physical domain at baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
83.3
± 19.54
Physical domain after 30 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
78.3
± 20.28
Physical domain after 90 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
80.0
± 17.78
Role domain at baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
80.0
± 7.45
Role domain after 30 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
90.0
± 6.97
Role domain after 90 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
86.7
± 11.18
Vitality domain at baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
75.0
± 16.67
Vitality domain after 30 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
73.3
± 6.97
Number of Participants With Exacerbation of Pulmonary DiseaseSecondary· 90 days
Hospitalization and/or antibiotics for respiratory infection or complication. Exacerbations of pulmonary disease were defined as respiratory infections that resulted in the requirement for hospitalization and/or antibiotics to treat the respiratory infection or complication. Hospitalizations that are part of routine care (e.g. hospital admissions for annual "tune-up") or antibiotics that are part of the regular treatment regimen were not documented as exacerbations. Occurrence of exacerbation related hospitalization OR the necessity of a prescription for antibiotics qualify as worsening diseas
Exacerbation of pulmonary disease at baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
2
Exacerbation that required antibiotics but not hospitalization at Day 30
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
1
Exacerbations that required antibiotics at Day 90
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
3
FEV1 (Actual)Secondary· 90 days
FEV1 is the actual volume measured in liters.
Forced expiratory volume in one second (FEV1): The forced expiratory volume-one second is the total volume of air a patient exhales in the first second during maximal effort. Normal range is \>80%. The patient takes a full breath in and exhale as hard and fast as they can. FEV1 refers to the volume of air that an individual can exhale during a forced breath in the first 1 second. Decreasing percentage is associated with worsening / severe disease
FEV1 measure at baseline (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1.8
± 0.94
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1.7
± 0.54
FEV1 measure after 30 days of therapy (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1.9
± 1.05
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1.6
± 0.71
FEV1 measure after 90 days of therapy (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
1.9
± 0.93
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
1.7
± 0.73
FEV1 (% Predicted)Secondary· 90 days
FEV1 Percent Predicted (FEV1 % Predicted) is the actual volume exhaled in the first 1 second, divided by the "Normal" value for that actual value for a person of that age, gender, height and weight. A nomogram based on population norms provides a series of "Normal Values."
FEV1: The forced expiratory volume-one second is the total volume of air a patient exhales in the first second during maximal effort. Normal range is \>80%. Decreasing percentage is associated with worsening / severe disease
FEV1 measure at baseline (% Predicted)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
55.2
± 25.49
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
58.6
± 19.49
FEV1 measure after 30 days of therapy (% Predicted)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
58.8
± 27.81
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
57.8
± 28.42
FEV1 measure after 90 days of therapy (% Predicted)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
60.4
± 24.76
Home Based Airway Clearance With Metaneb in Patients With Motor Neuron Disease.
59.4
± 27.67
FVC (Actual)Secondary· 90 days
FVC is the actual volume measured in liters.
The functional vital capacity (FVC) is the total volume of air a patient exhales for the total duration of the test during maximal effort. Normal range is \>80%. Decreasing percentage is associated with worsening / severe disease.
FVC was only done in CF subjects because performance of the test requires intact respiratory muscle function. CF patients have intact respiratory muscle function and can therefore perform this maneuver. Patients with Motor Neuron Disease suffer from progressive weakness of all muscles including the respiratory muscles. T
FVC at baseline (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2.6
± 0.98
FVC after 30 days of therapy (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2.6
± 1.08
FVC after 90 days of therapy (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
2.7
± 0.99
FVC (% Predicted)Secondary· 90 days
FVC Percent Predicted (FVC % Predicted) is the actual volume exhaled in the first 1 second, divided by the "Normal" value for that actual value for a person of that age, gender, height and weight. A nomogram based on population norms provides a series of "Normal Values."
The functional vital capacity is the total volume of air a patient exhales for the total duration of the test during maximal effort. Normal range is \>80%. Decreasing percentage is associated with worsening / severe disease.
FVC was only done in CF subjects because performance of the test requires intact respiratory muscle f
FVC at baseline (% Predicted)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
68.6
± 22.09
FVC after 30 days of therapy (% Predicted)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
69.8
± 23.19
FVC after 90 days of therapy (% Predicted)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb in Patients With Cystic Fibrosis.
71.0
± 21.30
FEV1/FVC RatioSecondary· 90 days
The proportion of the FVC expired in one second Results are given in both actual values (litres, litres per second) and %predicted-the test result as a percent of the "predicted values" for the patients of similar characteristics. Results over 80% are considered normal.
Patients with Motor Neuron Disease suffer from progressive weakness of all muscles including the respiratory muscles. The test results for FVC are affected muscle weakness and are therefore not a valid representation of their pulmonary function.
FEV1/FVC at baseline
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
78.4
± 19.78
FEV1/FVC after 30 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
81.4
± 18.42
FEV1/FVC after 90 days of therapy
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
82.4
± 14.54
SVC (Actual)Secondary· 90 days
Slow Vital Capacity (SVC) is the actual volume measured in liters.
Slow Vital Capacity displays the volume of gas measured on a complete expiration after a maximal inspiration without forced or rapid effort. Useful measurement when FVC is reduced, and airway obstruction is present. Educed SVC is associated with worsening respiratory disease.
Slow Vital Capacity provides the same measure as FVC - i.e. "Vital Capacity." It does not, however, require a "Forced expiratory maneuver (it requires a slow inspiration and slow expiration) and therefore is easier to achieve a valid result in patients w
SVC at baseline (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
2.1
± 0.50
SVC after 30 days of therapy (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
2.2
± 0.66
SVC after 90 days of therapy (Actual)
Group
Value
95% CI
Home Based Airway Clearance With Metaneb
2.1
± 0.89
Sponsor's own description
The study was a non-randomized open label pilot study. It was an observational design conducted at one (1) site in the US. All enrolled subjects received treatment with the MN4000.
This pilot study evaluated subject satisfaction with the therapy and adherence to the therapy during the 90-day treatment period, and also collected clinical outcome data. Outcomes were assessed before, during and after the MN4000 treatment period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
· Phase 1
· recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
· Phase 1
· recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine
· recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation.
· Phase 3
· recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI
· Phase 1, PHASE2
· active not recruiting
Other Hill-Rom trials
Trials by the same sponsor.
NCT04627272 — AutoDx-DR Prospective Clinical Validation Study Protocol
· NA
· unknown
NCT04582214 — Oscillation and Lung Expansion Therapy in Patients With COVID-19
· NA
· unknown
NCT04017312 — A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting
· NA
· terminated
NCT03645473 — Evaluation of Device Settings for Airway Clearance Using The Monarch Airway Clearance System
· NA
· unknown
NCT03628833 — Incontinence Management System ICU Field Evaluation
· NA
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hill-Rom
Last refreshed: 7 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03797677.